James Wilson, MD, PhD Receives Pioneer Award for Research on Gene Therapy & AAV Gene Delivery Syst

NEW ROCHELLE, N.Y. - April 30, 2014 - PRLog -- Contact: Vicki Cohn, Mary Ann Liebert, Inc, (914) 740-2100, ext. 2156, vcohn@liebertpub.com

James Wilson, MD, PhD Receives Pioneer Award for Research on Gene Therapy and AAV Gene Delivery Systems

New Rochelle, NY—James M. Wilson, MD, PhD (University of Pennsylvania Perelman School of Medicine, Philadelphia) has dedicated his research and medical career to developing gene therapy and the vectors needed to deliver genes into cells for the treatment and cure of inherited diseases. In recognition of his leadership and accomplishments, Dr. Wilson has received a Pioneer Award, bestowed by a blue ribbon panel*, from Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. Human Gene Therapy is commemorating its 25th anniversary by honoring the leading 12 Pioneers in the field of cell and gene therapy and publishing a Pioneer Perspective by each of the award recipients. The Perspective by Dr. Wilson is available on the Human Gene Therapy website (http://www.liebertpub.com/hum).

In his essay “Genetic Diseases, Immunology, Viruses, and Gene Therapy,” (http://online.liebertpub.com/doi/full/10.1089/hum.2014.2511) Dr. Wilson traces the path, motivating factors, and mentors and colleagues that led him from his early work identifying the mutations responsible for the devastating childhood disease Lesch-Nyhan syndrome (LNS) to the exploration of novel techniques and molecular tools for transferring therapeutic genes first into animals and then into humans. Since joining the faculty at the University of Pennsylvania more than 20 years ago, much of his research has focused on the development of adenoviral and adeno-associated viral vectors as vehicles for gene delivery.

Noting that the commercialization of gene therapy is still in its infancy, Dr. Wilson states that "We are entering a remarkable era of gene therapy research that will accelerate its development and lead to a number of commercial products across a spectrum of diseases." His laboratory has made seminal contributions to the basic biology of vectors and the development of current generation vector technologies that have enabled others to successfully move into the clinic.

"Dr. Wilson strongly deserves this accolade as an HGT pioneer of gene and cell therapy,” says Deputy Editor George Dickson, BSc, PhD, University of London, Surrey. “His unparalleled contributions to the adenoviral and AAV vector fields over more than 25 years have been profound and seminal. Vectors from Dr. Wilson's lab at the University of Pennsylvania have been distributed around the globe, and are bearing fruit in viral vaccine and viral gene therapy areas spanning a plethora of disease targets."

*The blue ribbon panel of leaders in cell and gene therapy, led by Chair Mary Collins, PhD, MRC Centre for Medical Molecular Virology, University College London selected the Pioneer Award recipients. The Award Selection Committee selected scientists that had devoted much of their careers to cell and gene therapy research and had made a seminal contribution to the field--defined as a basic science or clinical advance that greatly influenced progress in translational research.

About the Journal
Human Gene Therapy, the official journal of the European Society of Gene and Cell Therapy, British Society for Gene and Cell Therapy, French Society of Cell and Gene Therapy, German Society of Gene Therapy, and five other gene therapy societies, is an authoritative peer-reviewed journal published monthly in print and online. Led by Editor-in-Chief James M. Wilson, MD, PhD, Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Human Gene Therapy presents reports on the transfer and expression of genes in mammals, including humans. Related topics include improvements in vector development, delivery systems, and animal models, particularly in the areas of cancer, heart disease, viral disease, genetic disease, and neurological disease, as well as ethical, legal, and regulatory issues related to the gene transfer in humans. Its sister journals, Human Gene Therapy Methods, published bimonthly, focuses on the application of gene therapy to product testing and development, and Human Gene Therapy Clinical Development, published quarterly, features data relevant to the regulatory review and commercial development of cell and gene therapy products. Tables of content for all three publications and a free sample issue may be viewed on the Human Gene Therapy website (http://www.liebertpub.com/hum).

About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many areas of science and biomedical research, including Nucleic Acid Therapeutics, Tissue Engineering, Stem Cells and Development, and Cellular Reprogramming. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website (http://www.liebertpub.com).